Evidence map›Paper›PMID 40254670›Full record

ArticleCell death & disease2025

CITK modulates BRCA1 recruitment at DNA double strand breaks sites through HDAC6.

Giorgia Iegiani, Gianmarco Pallavicini, Alex Pezzotta, Alessia Brix, Alessia Ferraro, Marta Gai, Enrica Boda, Stephanie L Bielas, Anna Pistocchi, Ferdinando Di Cunto

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giorgia Iegiani *Neuroscience Institute Cavalieri Ottolenghi, Turin, Italy.ORCID http://orcid.org/0000-0003-2966-9675
Gianmarco Pallavicini *Neuroscience Institute Cavalieri Ottolenghi, Turin, Italy.
Alex PezzottaDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Italy.
Alessia BrixDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Italy.
Alessia FerraroNeuroscience Institute Cavalieri Ottolenghi, Turin, Italy.
Marta GaiDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy.
Enrica BodaNeuroscience Institute Cavalieri Ottolenghi, Turin, Italy.ORCID http://orcid.org/0000-0002-1006-2577
Stephanie L BielasDepartment of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA.
Anna PistocchiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Italy.ORCID http://orcid.org/0000-0001-9467-2542
Ferdinando Di CuntoNeuroscience Institute Cavalieri Ottolenghi, Turin, Italy. ferdinando.dicunto@unito.it.ORCID http://orcid.org/0000-0001-9367-6357

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG23341Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG29187Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) PhD fellowshipAssociazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) Post doctoral fellowshipMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) PhD fellowshipMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) PRIN-PNRR program n. 2022M75NN8Regione Piemonte (Region of Piedmont) INFRAP Locneuro
6 · The paper itself

Abstract

Citron Kinase (CITK) is a protein encoded by the CIT gene, whose pathogenic variants underlie microcephalic phenotypes that characterize MCPH17 syndrome. In neural progenitors, CITK loss leads to microtubule instability, resulting in mitotic spindle positioning defects, cytokinesis failure, and accumulation of DNA double strand breaks (DSBs), ultimately resulting in TP53-dependent senescence and apoptosis. Although DNA damage accumulation has been associated with impaired homologous recombination (HR), the role of CITK in this process and whether microtubule dynamics are involved is still unknown. In this report we show that CITK is required for proper BRCA1 localization at sites of DNA DSBs. We found that CITK's scaffolding, rather than its catalytic activity, is necessary for maintaining BRCA1 interphase levels in progenitor cells during neurodevelopment. CITK regulates the nuclear levels of HDAC6, a modulator of both microtubule stability and DNA damage repair. Targeting HDAC6 in CITK-deficient cells increases microtubule stability and recovers BRCA1 localization defects and DNA damage levels to that detected in controls. In addition, the CIT-HDAC6 axis is functionally relevant in a MCPH17 zebrafish model, as HDAC6 targeting recovers the head size phenotype produced by interfering with the CIT orthologue gene. These data provide novel insights into the functional interplay between HR and microtubule dynamics and into the pathogenesis of CITK based MCPH17, which may be relevant for development of therapeutic strategies.

Indexed as

BRCA1 ProteinDNA Breaks, Double-StrandedHistone Deacetylase 6Intracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesAnimalsDNA RepairHumansMicrotubulesZebrafishBRCA1 ProteinBRCA1 protein, humanHDAC6 protein, humanHistone Deacetylase 6Intracellular Signaling Peptides and ProteinsProtein Serine-Threonine Kinases

Identifiers

PMID40254670
PMCPMC12009987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.